替吉奥治疗初诊老年晚期非小细胞肺癌患者临床分析被引量：3

Clinical Analysis of S-1 in the Treatment of Newly Diagnosed Elderly Patients with Advanced Non-small-cell Lung Carcinoma

下载PDF

导出

摘要目的探讨替吉奥治疗初诊老年晚期非小细胞肺癌患者的近期疗效和毒副反应。方法 28例初诊老年晚期非小细胞肺癌患者均予单药替吉奥口服化疗,并评价近期疗效和毒副反应。结果 28例患者均可评价疗效,其中CR 2例,PR 4例,SD 12例,PD 10例,总有效率21.43%(6/28),临床受益率64.29%(18/28)。化疗相关主要毒副反应包括恶心、呕吐、腹泻、骨髓抑制、口腔黏膜炎等,其中Ⅲ、Ⅳ度骨髓抑制发生率为17.86%。结论替吉奥治疗初诊老年晚期非小细胞肺癌患者安全有效。 Objective To investigate the short-term efficacy and toxicities of S-1 in the treatment of newly diagnosed elderly patients with advanced non-small-cell lung carcinoma. Methods Twenty-eight newly diagnosed elderly patients with advanced non-small-cell lung carcinoma received the monotherapy S-1 oral chemotherapy,and the efficacy and toxicities were observed. Results Of the 28 patients evaluable for efficacy,CR was observed in the 2patients,PR in the 4 patients,SD in the 12 patients,PR in the 10 patients,the total response rate was 21. 43%（ 6 /28）,the clinical benefit rate was 64. 29%（ 18 /28）. The main toxicities were nausea,vomiting,diarrhea,myelosuppression,oral mucositis,the incidence of Ⅲ and Ⅳ degree myelosuppression was 17. 86%. Conclusion S-1 is safe and effect in the treatment of newly diagnosed elderly patients with advanced non-small-cell lung carcinoma.

作者沈预程吉浩明张燕谢锦华钱烨王彧

机构地区海安县人民医院

出处《肿瘤基础与临床》 2016年第1期29-31,共3页 journal of basic and clinical oncology

关键词替吉奥晚期非小细胞肺癌初诊老年患者 S-1 advanced non-small-cell lung carcinoma newly diagnosed elderly patients

分类号 R734.2 [医药卫生—肿瘤] R730.53 [医药卫生—肿瘤]

引文网络
相关文献

参考文献11

1Jemal A, Siegel R, Ward E, et al. Cancer statistics,2009 [ J ]. CA Cancer J Clin,2009,59(4) :225 -249.
2Shiroyama T,Kijima T,Komuta K,et aL Phase tailored S-1 regi- men study of first-line chemotherapy in elderly patients with ad- vanced and recurrent non-small cell lung cancer[ J]. Cancer Che- mother Pharmaco1,2012,70 ( 6 ) :783 - 789.
3Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Da- tabase survey [ J ]. J Thorac Oneol, 2010,5 ( 1 ) : 29 - 33.
4Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase Ⅲ study of cisplatin plus irinotecan versus earboplatin plus paelitaxel,cisplatin plus gemcitabine, and eisplatin plus vinorelbine for advanced non- small-cell lung cancer: Four-Ann Cooperative Study in Japan[ J]. Ann Onco1,2007,18 ( 2 ) : 317 - 323.
5Govindan R, Morgensztern D, Kommor MD, et al. Phase Ⅱ trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer[ J]. J Thorac Onco1,2011,6(4) :790 - 795.
6Hashizume T, Nakada Y. S-1 monotherapy in patients with pretrea- ted advanced non-small cell lung cancer[ J]. Gau To Kagaku Ryo- ho,2009,36 (6) :963 - 967.
7Shiroyama T, Komuta K, Imamura F, et al. Phase Ⅱ study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer[J]. Lung Cancer,2011,74( 1 ) :85 - 88.
8Shiroyama T, Kijima T, Komuta K,et al. Phase U tailored S-1 regi- men study of first-line chemotherapy in elderly patients with ad- vanced and recurrent non-small cell lung cancer[ J]. Cancer Che- mother Pharmacol,2012,70(6) :783 -789.
9Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonie acid of gastrointestinal toxicity of 5-fluorouraeil without loss of its antitu- mor activity in rats [ J ]. Cancer Res, 1993,53 ( 17 ) :4004 - 4009.
10Miyoshi S,ho R,Katayama H,et al. Phase 11 trial of S-1 as third- line or further chemotherapy in patients with advanced non-small- cell lung cancer [ J ]. Int J Clin Oncol,2014,19 ( 6 ) : 1005 - 1010.